Pharmaceutical composition containing cyclometalated N-heterocyclic carbene complexes for cancer treatment
US9822139B2 · kind B2 · utility
0Cited by
0References
29Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 7, 2013 |
| Grant date | Nov 21, 2017 |
| Priority date | — |
| Expiry date | May 13, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07F1/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure is related to a pharmaceutical composition for treatment of cancer comprising a cyclometalated N-heterocyclic carbene complex. The cyclometalated N-heterocyclic carbene complex contains a gold(III) or a platinum(II) atom. The pharmaceutical composition possesses anti-cancer activity such as the induction of cell death, inhibition of cellular proliferation, inhibition of topoisomerase and/or poisoning of topoisomerase.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.